125I粒子植入联合化疗治疗晚期非小细胞肺癌的近期疗效

摘要

目的 观察CT引导下放射性粒子125I植入联合化疗治疗晚期非小细胞肺癌(NSCLC)的近期疗效及并发症的发生情况.方法 术前经临床影像学及病理学检查确诊为Ⅲb-Ⅳ期NSCLC患者70例,其中32例在CT引导下行放射性粒子125I植入联合化疗(研究组);38例行单纯化疗(对照组),化疗方案为DP方案(多西他赛+顺铂).治疗后6个月复查胸部CT测量肿瘤体积,并评定疗效.结果 研究组和对照组有效率分别为84.38%(27/32)和42.11%(16/38),2组差异有统计学意义(χ2=13.100,P＜0.01).结论 放射性125I粒子植入联合化疗是一种有效、安全的治疗晚期NSCLC 的方法.%Objective To explore the short-term effect of CT guided radioactive particle I implantation combined with chemotherapy on advanced non-small cell lung cancer (NSCLC ) and the occurrence of complications .Methods Seventy patients with stage Ⅲb-Ⅳ NSCLC confirmed by preoperative clinical imaging and pathological examination were treated with chemotherapy regi -men (docetaxel plus cisplatin ) alone (control group , n=38 ) or in combination with CT guided radioactive particle 125 Ⅰ implantation (experimental group ,n= 32 ) .Tumor volume was measured by chest CT scanning 6 months after treatment .Curative efficacy was assessed according to tumor lesion classification and therapeutic evaluation criteria .Results The effective rate in experimental group (84.38% ,27/32) was significantly higher than that in control group (42.11% ,16/38) (x2 =13 .100 ,P<0 .01) .Conclusion Radioactive 125Ⅰ particle implantation combined with chemotherapy is an effective and safe treatment for advanced NSCLC .